Point of care DNA diagnostics: faster, better, cheaper

Vice President of Diagnostics, Spartan Bioscience
Monday September 22, 2014 12:00 - 13:00
Mackenzie Building Room 3356, Carleton University
abstract
Point of care or home use diagnostic tests are becoming more and more common. Imagine the day when you can have a Strep throat test right in the Dr's office or get screened before getting on a plane for flu. This future is getting closer and closer. Spartan Bioscience commercializes point of care DNA testing systems and hopes to make the above a reality in the not too distant future. I'll present some of the insights and challenges with product development in a new space and how technology, regulation and marketing work together to bring a diagnostic test to market
biography
Dr. Chris Harder is the VP of Diagnostics at Spartan Bioscience. Dr. Harder joined Spartan in 2006. As one of Spartan's first employees, Chris assembled the R&D team and invented many of the company's core technologies. Dr. Harder oversees the development of new diagnostic tests, reagent manufacturing, clinical affairs and regulatory affairs. Dr. Harder was the project manager on Spartan's first FDA 510(k) cleared test. Dr. Harder holds a bachelor's degree in biochemistry from the University of Ottawa, and a Ph.D. in biochemistry from the University of Ottawa.
Last updated September 12, 2014